A Study of [177Lu]Lu-DOTA-TATE in Newly Diagnosed ES-SCLC Patients in Combination With Carboplatin, Etoposide and Atezolizumab
Novartis
Novartis
Shanghai JMT-Bio Inc.
Merck Sharp & Dohme LLC
Shanghai Junshi Bioscience Co., Ltd.
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
InxMed (Shanghai) Co., Ltd.
BioNTech SE
NantCell, Inc.
Sichuan University
Sichuan University
Canadian Cancer Trials Group
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Abramson Cancer Center at Penn Medicine
Mereo BioPharma
G1 Therapeutics, Inc.
AbbVie
Abramson Cancer Center at Penn Medicine
Eli Lilly and Company
Milton S. Hershey Medical Center
Amgen
University of Alabama at Birmingham
Zhejiang Cancer Hospital
Hoosier Cancer Research Network
Alliance for Clinical Trials in Oncology
National Cancer Institute, Naples
Dana-Farber Cancer Institute
H. Lee Moffitt Cancer Center and Research Institute
University of Alabama at Birmingham